We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Seelos Therapeutics Inc (QB) | USOTC:SEEL | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.39 | 0.37 | 0.41 | 0.00 | 00:00:00 |
Seelos Therapeutics, Inc.
|
(Name of Issuer)
|
Common Stock, par value $0.001
|
(Title of Class of Securities)
|
81577F406
|
(CUSIP Number)
|
October 31, 2024
|
(Date of Event Which Requires Filing of the Statement)
|
☒ |
Rule 13d-1(b)
|
☐ |
Rule 13d-1(c)
|
☐ |
Rule 13d-1(d)
|
Cusip No. 81577F406
|
Page 2 of 5 Pages
|
1.
|
NAME OF REPORTING PERSONS
AdvisorShares Trust
|
|||
2.
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a) ☐
(b) ☐
|
|||
3.
|
SEC USE ONLY
|
|||
4.
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
|||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
WITH
|
5.
|
SOLE VOTING POWER
|
152,444 | |
6.
|
SHARED VOTING POWER
|
0 | ||
7.
|
SOLE DISPOSITIVE POWER
|
152,444 | ||
8.
|
SHARED DISPOSITIVE POWER
|
0 | ||
9.
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
152,444 | ||
10.
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
|
☐ | ||
11.
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
|
34.96% | ||
12.
|
TYPE OF REPORTING PERSON (See Instructions)
|
IV | ||
Cusip No. 81577F406
|
Page 3 of 5 Pages
|
Item 1(a). |
Name of Issuer: Seelos Therapeutics, Inc.
|
Item 1(b). |
Address of Issuer’s Principal Executive Offices:
|
Item 2(a). |
Name of Person Filing: AdvisorShares Trust
|
Item 2(b). |
Address of Principal Business Office or, if none, Residence:
|
Item 2(c). |
Citizenship: Delaware
|
Item 2(d). |
Title of Class of Securities: Common Stock, par value, $0.001
|
Item 2(e). |
CUSIP Number: 81577F406
|
Item 3. |
If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
|
(a)
|
[ ]
|
Broker or dealer registered under Section 15 of the Act (15 U.S.C 78o);
|
|
(b)
|
[ ]
|
Bank as defined in Section 3(a)(6) of the Act (15 U.S.C 78c);
|
|
(c)
|
[ ]
|
Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C 78c);
|
|
(d)
|
[X]
|
Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
|
|
(e)
|
[ ]
|
An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
|
|
(f)
|
[ ]
|
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
|
|
(g)
|
[ ]
|
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
|
|
(h)
|
[ ]
|
A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
|
|
(i)
|
[ ]
|
A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
|
|
(j)
|
[ ]
|
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
|
|
(k)
|
[ ]
|
Group, in accordance with § 240.13d-1(b)(1)(ii)(K).
|
Cusip No. 81577F406
|
Page 4 of 5 Pages
|
Item 4. |
Ownership:
|
(a) |
Amount beneficially owned: 152,444
|
(b) |
Percent of Class: 34.96%
|
(c) |
Number of shares as to which such person has:
|
(i) |
sole power to vote or to direct the vote: 152,444
|
(ii) |
shared power to vote or to direct the vote: 0
|
(iii) |
sole power to dispose or to direct the disposition of: 152,444
|
(iv) |
shared power to dispose or to direct the disposition of: 0
|
Item 5. |
Ownership of Five Percent or Less of a Class:
|
Item 6. |
Ownership of More than Five Percent on Behalf of Another Person:
|
Item 7. |
Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:
|
Item 8. |
Identification and Classification of Members of the Group:
|
Item 9. |
Notice of Dissolution of Group:
|
Cusip No. 81577F406
|
Page 5 of 5 Pages
|
November 5, 2024
|
|
(Date)
|
|
/s/ Stefanie Little
|
|
(Signature)
|
|
Stefanie Little – Chief Compliance Officer
|
|
Name and Title
|
1 Year Seelos Therapeutics (QB) Chart |
1 Month Seelos Therapeutics (QB) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions